Table 1.
Summary results for newly identified risk loci
| Nearest genea | Risk allele (frequency) | Discovery GWAS meta-analysis | UK Replication 1 | UK Replication 2 | Meta-analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Position (hg19, bp) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | I2 (%) | P het | |||
| 3q28, rs4459895 | LPP | A (0.20) | 187954414 | ||||||||||
| cHL | 4.16 × 10−10 | 1.27 (1.18–1.36) | 6.85 × 10−9 | 1.44 (1.27–1.63) | 0.02 | 1.26 (1.04–1.52) | 4.45 × 10−18 | 1.30 (1.23–1.38) | 13 | 0.33 | |||
| NSHL | 9.16 × 10−9 | 1.37 (1.23–1.53) | 1.37 × 10−8 | 1.43 (1.26–1.62) | 0.04 | 1.30 (1.02–1.66) | 9.43 × 10−17 | 1.39 (1.28–1.50) | 0 | 0.93 | |||
| MCHL | 0.92 | 1.04 (0.91–1.19) | 0.98 | 1.00 (0.68–1.47) | 0.55 | 1.04 (0.92–1.19) | 0 | 0.82 | |||||
| 6q22.33, rs9482849 | PTPRK | C (0.17) | 128288536 | ||||||||||
| cHL | 5.02 × 10−8 | 1.24 (1.15–1.35) | 0.13 | 1.11 (0.97–1.27) | 0.13 | 1.17 (0.95–1.43) | 1.52 × 10−8 | 1.20 (1.13–1.28) | 3 | 0.39 | |||
| NSHL | 2.91 × 10−6 | 1.32 (1.17–1.48) | 0.17 | 1.10 (0.96–1.25) | 0.20 | 1.19 (0.91–1.54) | 4.13 × 10−6 | 1.21 (1.12–1.33) | 10 | 0.35 | |||
| MCHL | 0.17 | 1.11 (0.96–1.28) | 0.78 | 1.06 (0.70–1.61) | 0.16 | 1.10 (0.96–1.26) | 0 | 0.97 | |||||
| 6q23.3, rs6928977 | AHI1 | G (0.57) | 135626348 | ||||||||||
| cHL | 1.66 × 10−8 | 1.18 (1.12–1.26) | 0.01 | 1.14 (1.03–1.26) | 0.05 | 1.16 (1.00–1.34) | 1.24 × 10−10 | 1.17 (1.12–1.23) | 0 | 0.85 | |||
| NSHL | 9.34 × 10−10 | 1.31 (1.20–1.42) | 0.03 | 1.12 (1.01–1.24) | 0.01 | 1.30 (1.06–1.58) | 4.62 × 10−11 | 1.23 (1.16–1.31) | 26 | 0.25 | |||
| MCHL | 0.24 | 1.06 (0.96–1.18) | 0.69 | 1.06 (0.79–1.42) | 0.22 | 1.06 (0.96–1.17) | 0 | 0.22 | |||||
| 10p14, rs3781093 | GATA3 | T (0.88) | 8101927 | ||||||||||
| cHL | 4.89 × 10−12 | 1.35 (1.23–1.47) | 4.00 × 10−4 | 1.32 (1.25–1.44) | 0.11 | 1.21 (0.96–1.52) | 4.91 × 10−12 | 1.28 (1.19–1.37) | 64 | 0.01 | |||
| NSHL | 9.16 × 10−12 | 1.53 (1.36–1.75) | 2.00 × 10−4 | 1.44 (1.31–1.61) | 0.64 | 0.92 (0.68–1.26) | 9.49 × 10−13 | 1.39 (1.28–1.53) | 61 | 0.06 | |||
| MCHL | 0.03 | 1.18 (1.02–1.36) | 0.05 | 1.56 (1.02–2.40) | 0.16 | 0.91 (0.79–1.04) | 73 | 0.03 | |||||
| 13q34, rs112998813 | UPF3A | C (0.08) | 115059729 | ||||||||||
| cHL | 3.63 × 10−3 | 1.19 (1.06–1.33) | 0.03 | 1.23 (1.03–1.47) | 0.43 | 1.12 (0.84–1.50) | 2.70 × 10−4 | 1.19 (1.08–1.30) | 13 | 0.32 | |||
| NSHL | 8.43 × 10−8 | 1.58 (1.34–1.88) | 0.03 | 1.22 (1.02–1.47) | 0.28 | 1.23 (0.85–1.78) | 4.58 × 10−8 | 1.39 (1.23–1.56) | 27 | 0.24 | |||
| MCHL | 0.92 | 0.99 (0.80–1.22) | 0.27 | 1.35 (0.80–2.23) | 0.75 | 1.03 (0.85–1.25) | 0 | 0.56 | |||||
| 16p13.13, rs34972832 | CLEC16A | A (0.18) | 11198938 | ||||||||||
| cHL | 1.45 × 10−4 | 1.15 (1.07–1.23) | 6.34 × 10−3 | 1.18 (1.05–1.34) | 0.10 | 1.17 (0.97–1.42) | 8.03 × 10−7 | 1.16 (1.09–1.23) | 6 | 0.37 | |||
| NSHL | 7.47 × 10−7 | 1.24 (1.15–1.34) | 6.53 × 10−3 | 1.30 (1.17–1.45) | 0.28 | 1.15 (0.89–1.50) | 2.12 × 10−8 | 1.24 (1.15–1.34) | 37 | 0.18 | |||
| MCHL | 0.65 | 0.97 (0.85–1.11) | 0.91 | 1.02 (0.69–1.52) | 0.70 | 0.98 (0.86–1.10) | 0 | 0.94 | |||||
The risk allele is the allele corresponding to the estimated odds ratio. Frequency of the risk allele is from the CEU population from 1000 Genomes Project
cHL classical Hodgkin lymphoma, NSHL nodular sclerosis Hodgkin lymphoma, MCHL mixed cellularity Hodgkin lymphoma, bp base pair, OR odds ratio, CI confidence interval, I2 proportion of the total variation due to heterogeneity
I2 value ≥ 75% is considered to be characteristic of large heterogeneity
aNearest gene may not be the functional gene